ArticleMethods in molecular biology (Clifton, N.J.)2026
Engineering Functional Skeletal Muscle Tissues from Human Induced Pluripotent Stem Cells.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In vitro cell culture models of human skeletal muscle offer a valuable platform for studies of pathology and discovery of new therapeutics. However, traditional two-dimensional cell culture models suffer from limited durability and challenges with assessment of skeletal muscle contractile function. Furthermore, finite proliferation potential and scarce availability of patient-derived primary myoblasts limit experimental throughput when using these cells. Here, we describe a method for using human induced pluripotent stem cells (hiPSCs) to generate functional three-dimensional skeletal muscle tissues. Briefly, transient overexpression of Pax7 in hiPSC-derived paraxial mesoderm cells permits efficient formation of myogenic progenitor cells (iMPCs), which are then combined with hydrogel matrix to form cylindrically shaped skeletal muscle (iSKM) "myobundles." After 2 weeks of differentiation, iSKM myobundles contain aligned and densely packed multinucleated myotubes that, in response to electrical stimulation, exhibit robust calcium transients and positive force-frequency and force-length relationships. The methods detailed here have been successfully utilized to model and study limb-girdle muscular dystrophy type R2/2B and can be applied for studies of skeletal muscle regeneration and testing of candidate gene and cell therapies for disease. Collectively, iSKM myobundle engineering is a powerful in vitro methodology expected to significantly advance human skeletal muscle research and therapy.
Indexed as
Identifiers
42867818What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.